Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
NCT ID: NCT01439373 Phase: PHASE2 Status: COMPLETED Enrollment: 16 Completion: 2011-12-05
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805, Pegylated interferon alfa-2a, Ribavirin, GSK2336805 Matching Placebo
Summary
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and ribavirin in subjects with chronic hepatitis C (CHC).
Primary Outcome
Number of Participant Achieving Rapid Virological Response (RVR) at Day 28, Nominal Analysis